Life Biosciences and Forge Biologics have formed a manufacturing partnership to support the development of Life Bio's partial epigenetic reprogramming platform for addressing aging-related diseases. The collaboration will specifically focus on advancing Life Bio's lead program targeting ophthalmic indications. The partnership aims to leverage Forge Biologics' expertise in manufacturing and gene therapy to accelerate the development of novel therapies for age-related diseases.

Figure .1 A Partnership Agreement for The Manufacture of Gene Therapy Is Signed by Life Biosciences and Forge Biologics

Figure 1 shows Timothy J. Miller, CEO, president, and co-founder of Forge Biologics, expressed excitement about the partnership with Life Biosciences. He referred to Life Bio as an emerging leader in developing therapies for aging-related diseases and highlighted Forge's role as the cGMP manufacturing partner for Life Bio's cellular rejuvenation technology. Miller emphasized the potential of this technology to benefit millions of aging patients globally.

As part of the partnership, Forge Biologics will offer various services to Life Biosciences, including adeno-associated virus (AAV) process development, toxicology, current good manufacturing practices (cGMP), and analytical services. Forge will utilize its platform processes, such as the HEK293 suspension Ignition Cells™ and pEMBR™ adenovirus helper plasmid. All development and manufacturing activities related to AAV will take place at Forge's gene therapy facility called the Hearth, located in Columbus, OH. The collaboration aims to leverage Forge's expertise and infrastructure to support the advancement of Life Biosciences' cellular rejuvenation technology for aging-related diseases.

Jerry McLaughlin, CEO of Life Biosciences, continued, "We believe we're on the threshold of revolutionising medicine with our cellular rejuvenation capabilities across a number of aging-related diseases, including ophthalmic conditions that include retinal ganglion cell failure. "As we move closer to the first human clinical trials and continue to develop treatments to reverse diseases of ageing by restoring cells to a more youthful state," the company said, "we are confident that our partnership with Forge will have a tremendous impact on our ability to enhance the speed and quality with which we can manufacture our therapeutic candidates."[1]

References:

1. https://www.genengnews.com/news/life-biosciences-and-forge-biologics-sign-gene-therapy-manufacturing-partnership-agreement/

Cite this article:

Janani R (2023),A Partnership Agreement for The Manufacture of Gene Therapy Is Signed by Life Biosciences and Forge Biologics, Anatechmaz, pp.289